Altre lingue Korro Bio, Inc.

Azioni

KRRO

US5009461089

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 19/04/2024			Variaz. 5gg	Var. 1 gen.
66,74 ^USD	-0,06%		-10,99%	+39,24%

28/03	KORRO BIO, INC. : HC Wainwright ottimista sul caso	ZM
27/03	KORRO BIO, INC. : RBC Capital Markets mantiene la raccomandazione Buy	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Korro Announces $70 Million Private Placement	18/04
Korro Bio, Inc. announced that it expects to receive $69.959848 million in funding from Atlas Venture L.P.	17/04
Korro to Participate in Upcoming Investor Conferences	01/04
Korro Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress	26/03
North American Morning Briefing : Stocks Struggle After New Records	22/03
North American Morning Briefing : Inflation -2-	15/03
Korro Bio: Development and Application of Graph Neural Networks to Design Guide Oligonucleotides that Promote RNA Editing	13/03
Korro to Present at the TD Cowen 44th Annual Health Care Conference	27/02
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio	18/01
Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference	04/01
Korro Announces Selection of Its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency	07/12
Korro Bio, Inc. Appoints Rachel Meyers as Board of Directors, Member of Nominating and Corporate Governance Committee	28/11
Frequency Therapeutics, Inc.(NasdaqCM:FREQ) dropped from NASDAQ Composite Index	03/11
Korro Bio, Inc. completed the acquisition of Frequency Therapeutics, Inc. from a group of shareholders.	03/11
Frequency Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11
FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ	06/10/23
Frequency Therapeutics : Termination of Material Agreement - Form 8-K	27/09/23
North American Morning Briefing : Stock Futures -2-	27/09/23
Frequency Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Korro Bio, Inc.

Azioni

KRRO

US5009461089

Altre lingue

Filtri